Payment overview · 2025
General Payments
$731.10
37 reported records · 12 companies
Healthcare provider profile · identity verified
Scott N Harder, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · AUGUSTA, KS · NPI 1932166154
Verified facts
What the public records show
CMS Open Payments records show Scott N Harder, D.O. received $731.10 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.87 | 24.2% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $97.50 | 13.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.82 | 12.6% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.75 | 10.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $67.52 | 9.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.71 | 7.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.61 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.32 | 4.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.34 | 4.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $26.79 | 3.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.40 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.47 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $731.10 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $112.21 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $97.50 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $75.09 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $74.75 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.63 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $67.52 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.81 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $26.40 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
189 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 631 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 403 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 87 |
| Omeprazole | Omeprazole | 386 | 76 |
| Losartan Potassium | Losartan Potassium | 328 | 76 |
| Potassium Chloride | Potassium Chloride | 297 | 48 |
| Lisinopril | Lisinopril | 216 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 48 |
| Eliquis | Apixaban | 189 | 27 |
| Warfarin Sodium | Warfarin Sodium | 187 | 20 |
| Sertraline Hcl | Sertraline Hcl | 184 | 35 |
| Metformin Hcl | Metformin Hcl | 177 | 42 |
| Simvastatin | Simvastatin | 177 | 38 |
| Furosemide | Furosemide | 169 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 40 |
| Gabapentin | Gabapentin | 154 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 23 |
| Tramadol Hcl | Tramadol Hcl | 124 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 29 |
| Allopurinol | Allopurinol | 119 | 23 |
| Carvedilol | Carvedilol | 115 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 22 |
| Trazodone Hcl | Trazodone Hcl | 95 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 28 |
| Bumetanide | Bumetanide | 89 | 15 |
| Levetiracetam | Levetiracetam | 86 | 12 |
| Buspirone Hcl | Buspirone Hcl | 80 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | suppressed |
| Famotidine | Famotidine | 75 | 18 |
| Montelukast Sodium | Montelukast Sodium | 75 | 15 |
| Fenofibrate | Fenofibrate | 74 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 17 |
| Jardiance | Empagliflozin | 69 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 68 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 65 | 11 |
| Ozempic | Semaglutide | 64 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 12 |
| Finasteride | Finasteride | 59 | 12 |
| Mirtazapine | Mirtazapine | 59 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 19 |
| Spironolactone | Spironolactone | 58 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 57 | 12 |
| Metformin Hcl Er | Metformin Hcl | 57 | 12 |
| Meloxicam | Meloxicam | 56 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 13 |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 20 |
| Atenolol | Atenolol | 48 | 12 |
| Sucralfate | Sucralfate | 48 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 48 | 11 |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 12 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Nystatin | Nystatin | 37 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 25 |
| Cephalexin | Cephalexin | 29 | 19 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Prednisone | Prednisone | 28 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Risperidone Odt | Risperidone | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 14 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Azathioprine | Azathioprine | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Fluorometholone | Fluorometholone | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Budesonide Dr | Budesonide | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $731.10 · 37 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, Fluad, Flucelvax, INTELLIS ADAPTIVESTIM, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error